

10. G.J. Quigley, A.H. J. Wang, G. Ughetto, G.V. Marel, J.H. Van Boom, and A. Rich, *Proc. Natl. Acad. Sci. U.S.A.* **77**, 7204 (1980).
11. D.J. Patel, S.A. Kozlowski, and J.A. Rice, *Proc. Natl. Acad. Sci. U.S.A.* **78**, 3333 (1981).
12. M.J. Moon, M.S. Jhon, and Y.K. Kang, *Bull. Korean Chem. Soc.*, **4**, 133 (1983).
13. Y.K. Kang and M.S. Jhon, *Macromolecules*, **17**, 138 (1984).
14. A.J. Hofinger, "Conformational Properties of Macromolecules", Academic, New York, 1973.
15. V. Nakata and A.J. Hopfinger, *FEBS Lett.*, **117**, 259 (1980).
16. C.N. Yoon, Y.K. Kang, and M.S. Jhon, *Biopolymers*, **23**, 511 (1984).
17. D.A. Brant, *Ann. Rev. Biophys. Bioeng.*, **1**, 369 (1972).
18. R. Fletcher and C.M. Reeves, *Computer J.*, **7**, 149 (1964).
19. W.E. Morf and W. Simon, *Helv. Chim. Acta*, **54**, 794 (1971).
20. J.E. Huheey, "Inorganic Chemistry", Haper and Row, New York, 1978. p. 40.
21. M.J. Moon and M.S. Jhon, *Bull. Chem. Soc. Japan*, **59**, 1215 (1986).
22. M. Sano and H. Yamatera, "Ions and Molecules in Solution", Ed. by N. Tanaka, H. Ohtaki, and R. Tamamushi, Elsevier, New York, 1983, p. 109.
23. R. Fletcher, "Fortran Subroutines for Minimization by Quasi-Newton Methods", AERE Report R7125, 1972.
24. M.M. Fishman and I. Schwartz, *Biochem. Pharm.*, **23**, 2147 (1974).
25. M. Spinelli and J.C. Dabrowiak, *Biochemistry*, **21**, 5862 (1982).
26. R. Kiraly and R.B. Martin, *Inorg. Chim. Acta*, **46**, 221 (1980).
27. J.R. Brown, in "Progress in Medicinal Chemistry", Vol. 15, Ed. by G.P. Ellis and G.B. West, Elsevier/North-Holland Biomedical Press, 1978, p. 125.
28. Y.K. Kang and M.S. Jhon, *Theoret. Chim. Acta*, **61**, 41 (1982).
29. W.J. Orville-Thomas, Ed., "Internal Rotation in Molecules", Wiley, New York, 1974.
30. C.N. Yoon and M.S. Jhon, *J. Comput. Chem.*, **7**, 189 (1986).
31. Y.P. Varshni, *Rev. Modern Phys.*, **29**, 664 (1957).

Liquid Chromatographic Resolution of Racemic Drugs on Various α -Arylalkylamine Derived Chiral Stationary Phases

Myung Ho Hyun*

Department of Chemistry, College of Natural Sciences, Pusan National University, Pusan 607

William H. Pirkle

Department of Chemistry, University of Illinois, Urbana, Illinois 61801, U.S.A. Received November 25, 1986

After conversion to their 3,5-dinitrobenzoyl or 3,5-dinitroanilide derivatives, the enantiomers of a number of drugs may be chromatographically separated on various α -arylalkylamine-derived chiral stationary phases (CSPs). While each CSP used in this study is useful, CSP **1** is best able to resolve the 3,5-dinitroanilide derivative of Ibuprofen while CSP **9** generally gives rather large α values for the resolution of 3,5-dinitrobenzoyl derivatives of the enantiomers of β -adrenergic blocking drugs.

Introduction

Direct chromatographic resolution of enantiomers on chiral stationary phases (CSP's) is now understood as the most rapid, sensitive, accurate and convenient means for determining enantiomeric purity and absolute configuration. In addition, this technique provides the preparative means for obtaining enantiomerically pure samples which may be needed for a variety of purposes. Owing to their potential utility, the development of effective CSPs has challenged a great many workers¹.

In recent years, our efforts have been focused on the development of new CSPs and the application of these CSPs to the resolution of various racemates. In the course of this work, we prepared α -arylalkylamine derived CSPs **1-9** which prove to be able to resolve the enantiomers of a wide variety of racemates²⁻⁵. As a general rule, the enantiomers separated

by these CSPs must initially be derivatized with an appropriate achiral π -acid reagent owing to the chiral recognition requirements of these CSP.

Among various racemates which are resolvable upon CSP **1-9**, are a number of interesting drugs. It is well known that enantiomers of drugs frequently show quantitatively different pharmacological properties, possibly because one enantiomer better fits the receptor site that does the other⁶. For the study of pharmacokinetics of drug enantiomers, chromatographic determinations of enantiomer concentrations on chiral columns have been suggested as a superior method⁷.

We have briefly reported the resolution of several racemic β -adrenergic blocking drugs on CSP **7**³. Since each of CSPs **1-9** shows somewhat different abilities to separate drug enantiomers, we now compare the ability of the various α -arylalkylamine-derived CSPs to separate the enantiomers of selected drug derivatives.

Experimental

Preparation of the CSPs used in this study either has been reported²⁻⁵ or will be reported elsewhere. The CSPs were bonded to 5 μ Spherisorb and packed into 4.6 \times 250 mm stainless steel columns as methyl alcohol slurries using conventional methods. Chromatography was performed by using an Altex 100 A pump, an Altex 210 injector, an Altex 152 dual wavelength (254 and 280 nm) or an Altex 165 variable wavelength UV detector and a Kipp-Zonen BD 41 recorder. Melting points were taken on a Büchi apparatus and are un-




Table 1. Resolution of Racemic Drug Derivatives upon Various α -Arylalkylamine Based Chiral Stationary Phases

Drugs	CSP 1			CSP 2			CSP 3		
	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c
Propranolol ^d	1.10	4.3		1.33	1.3		1.39	1.0	
Propranolol ^e	1.25	14.6	R	1.15	4.8	R	1.27	4.2	R
Alprenolol ^f	1.22	9.9		1.21	2.3		1.21	2.3	
Oxoprenolol ^f	1.20	10.9		1.17	2.5		1.26	2.6	
Metoprolol ^f	1.23	16.0		1.34	5.0		1.82	4.9	
Ephedrin ^f	1.14	13.7		1.98	5.6		3.27	5.1	
Amphetamine ^d	1.11	15.4	R	1.40	9.1	S	1.12	6.5	S
Ibuprofen ^f	3.16	8.5		2.27	2.8		2.95	1.6	

Drugs	CSP 4			CSP 5			CSP 6		
	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c
Propranolol ^d	1.28	2.0		1.28	2.1		1.40	2.0	
Propranolol ^e	1.48	11.0	R	1.40	14.9	R	1.33	9.5	R
Alprenolol ^f	1.39	5.3		1.31	8.4		1.31	5.0	
Oxoprenolol ^f	1.41	5.9		1.41	9.6		1.30	5.5	
Metoprolol ^f	2.26	11.1		2.05	14.4		1.66	10.7	
Ephedrin ^f	2.31	24.4		1.87	19.7		1.69	11.5	
Amphetamine ^d	1.32	12.6	S	1.40	12.6	S	1.45	17.3	S
Ibuprofen ^f	1.72	4.5		1.41	4.9		1.53	8.0	

Drugs	CSP 7			CSP 8			CSP 9		
	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c	α^a	$k'_1{}^{a,b}$	c^c
Propranolol ^d	1.63	2.1		1.29	1.2		1.53	1.2	
Propranolol ^e	1.24	13.3	R	1.21	3.9	R	2.70	3.6	R
Alprenolol ^f	1.24	7.1		1.23	1.8		1.14	1.8	
Oxoprenolol ^f	1.23	8.0		1.19	2.0		1.18	2.1	
Metoprolol ^f	1.52	14.0		1.43	3.9		1.16	3.9	
Ephedrin ^f	1.48	12.9		2.99	5.0		1.76	4.5	
Amphetamine ^d	1.51	2.1	S	1.35	8.7	S	1.68	9.7	S
Ibuprofen ^f	1.17	11.6		2.80	2.4		1.61	5.8	

^aSee reference 14 for definition. ^bMobile phase is 20% isopropyl alcohol in *n*-hexane except on CSP 1. Mobile phase for the resolution on CSP 1 is 10% isopropyl alcohol in *n*-hexane. Flow rate is 2 ml/min. ^cAbsolute configuration of the second eluted enantiomer. For blanks, elution orders have not been established. ^dN-3,5-Dinitrobenzoyl derivative. ^eBis 3,5-dinitrobenzoyl derivative. ^f3,5-Dinitroanilide derivative.

corrected. ¹H NMR were recorded on either a Varian EM-390 or Varian XL-200 spectrometer using tetramethylsilane as an internal standard. Infrared spectra were recorded on a Perkin-Elmer 1320 spectrometer. High resolution mass spectra were obtained on a varian 731 mass spectrometer.

All 3,5-dinitrobenzoyl derivatives of racemic drugs used in this study can be prepared using standard Shotten-Bauman procedures. Hence, we report the preparation of but one 3,5-dinitrobenzoyl derivative of a racemic drug as an example of the procedure used.

N-(3,5-Dinitrobenzoyl)propranolol. Propranolol hydrochloride (148 mg, 0.5 mmole) was suspended into 15 ml of CH₂Cl₂. To this was added triethylamine (120 mg, 0.17 ml, 1.2 mmole) and 3,5-dinitrobenzoyl chloride (110 mg, 0.48 mmole). After stirring for 10 min. at room temperature, the reaction mixture was washed with 1 N NaOH, 1 N HCl and

H₂O. The organic layer was dried over anhydrous Na₂SO₄ and used for HPLC analysis. After purification of the unused portion by preparative TLC, A yellow solid was obtained. mp 161–163°C; ¹H NMR(CDCl₃) δ 1.36 (d, 6H), 3.67–4.00 (m 3H), 4.07–4.50 (m, 4H), 6.73–5.93 (m, 1H), 7.30–7.53 (m, 4H), 7.70–7.85 (m 2H), 8.50–8.55 (m, 2H), 8.90–9.05 (m, 1H). IR (Nujol) 3460, 1625, 1580, 1538 cm⁻¹. High resolution mass spectrum calcd. for C₂₃H₂₃N₃O₇: 453.1536, found: 453.1532.

3,5-Dinitroanilide of Ibuprofen. Ibuprofen (206 mg, 1 mmole), thionyl chloride (5 ml) and 1 drop of pyridine in a 50 ml round bottom flask were refluxed for 1.5 hr with stirring. After removing excess thionyl chloride under vacuo, the residue was dissolved in 20 ml of CH₂Cl₂ and then treated with 3,5-dinitroaniline (275 mg, 1.5 mmole) and several drops of triethylamine for 30 min. The reaction mixture was washed




Figure 1. The resolution of 3,5-dinitroanilide derivative of Ibuprofen on CSP 7 using 20% isopropyl alcohol in *n*-hexane as a mobile phase.

with 1 N NaOH, 1 N HCl and H₂O. The organic layer was dried over anhydrous Na₂SO₄ to afford a sample solution for HPLC. Purification by preparative TLC afforded a white solid (304 mg, 82%). mp 194–195°C; ¹H NMR(CDCl₃) δ 0.90 (d, 6H), 1.58 (d, 3H), 1.80–2.05 (m, 1H), 2.45 (d, 2H), 3.73 (q, 1H), 7.00–7.23 (m, 4H), 7.62 (broad s, 1H), 8.60 (broad s, 3H). IR (Nujol) 3260, 3100, 1670, 1605, 1528 cm⁻¹. High resolution mass spectrum calcd. For C₁₉H₂₁N₃O₅; 371.1481, found: 371.1475.

Results and Discussion

Various α -adrenergic blocking drugs, as their N-3,5-dinitrobenzoyl derivatives, resolved quite well on CSPs 1–9. The N-3,5-Dinitrobenzoyl derivative of the central nervous system stimulant, amphetamine, and the 3,5-dinitroanilide derivative of the antiinflammatory agent, Ibuprofen also resolved well on CSPs 1–9. Pertinent chromatographic data appear in Table 1 and a chromatogram of the resolution of the Ibuprofen derivative is shown in Figure 1.

As shown in Table 1, each CSP affords characteristic resolution behavior. For example, CSP 1 shows the best result for the resolution of the 3,5-dinitroanilide derivative of Ibuprofen. CSP 3 shows the largest α value for the resolution of the ephedrin derivative. CSP 9 shows the best result for the resolution of the bis-(3,5-dinitrobenzoyl) derivative of Propranolol while CSP 7 shows the best result for the resolution of mono 3,5-dinitrobenzoyl derivative of Propranolol. No chiral recognition mechanism is proposed to account for these differences. Conceivably, there is an averaging between two competing chiral recognition mechanisms as has been reported for the resolution of series of N-(3,5-dinitrobenzoyl)- α -arylalkylamines upon α -arylalkylamine derived CSPs³. However, we can generally conclude that CSP 7 can be used for the resolution of β -blocking drugs while CSP 1 can be successfully used for the resolution of drugs similar to Ibuprofen. In addition, CSP 1 is quite attractive for the resolution of racemic drugs since it is relatively easy to prepare from the commercially available (R)-1-naphthylethylamine.

Among β -adrenergic blockers, racemic Propranolol is the most widely used for the treatment of cardiac dysrhythmias and hypertension. The (S)-enantiomer is known to have 100 times more β -adrenergic blocking activity than does the (R)-enantiomer⁸. Resolution of racemic Propranolol has been achieved by chromatography on silica of the diastereomeric

derivatives of either (R)- or (S)-phenylethylisocyanate⁹ or (R,R)- or (S,S)-tartaric acid¹⁰. Propranolol and ephedrin have also been resolved on commercially available chiral N-(3,5-dinitrobenzoyl)-phenylglycine columns as the oxazoline derivatives^{11,12}. However, the easy preparation of 3,5-dinitrobenzoyl derivatives of β -adrenergic blocking drugs and the large α values noted on the α -arylalkylamine-derived CSPs make the latter approach particularly attractive. We note that the enantiomers of a number of drugs may be separated *without derivatization* on commercially available immobilized α -glycoprotein columns¹³. Offsetting this advantage, these columns are rather expensive and alleged to sometimes be short-lived.

In conclusion, the easy separation of important racemic drugs upon α -arylalkylamine-derived CSPs may prove useful for pharmacological studies because this technique can be used either preparatively or to monitor the enantiomeric composition of the minute quantities of drugs isolated from whole blood or urine specimens. Such analysis, previously difficult or impossible, is vastly facilitated by chiral chromatographic columns. Procedures for analysis of the enantiomeric composition of β -adrenergic blocking drugs obtained from samples of body fluid are now being developed in our laboratories.

Acknowledgement. This work was partially supported by a grant from the National Science Foundation (USA). The grant to MHH from GINSCO is acknowledged.

References

- For review see (a) V.A. Davenkov, V.A. Kurganov, and A.S. Bochkov, in *Advances in Chromatography* Vol. 21 (J.C. Giddings, E. Grushka, and R.P. Brown, Eds.) pp 71-116 Marcell Dekker, New York (1984); (b) S. Allenmark, *J. Bioch. Biophys. Meth.* **9**, 1 (1984); (c) W.H. Pirkle, and J.M. Finn, in *Asymmetric Synthesis* Vol. 1 (J.D. Morrison, Ed.) pp 87-124 Academic Press, New York (1983).
- W.H. Pirkle, and M.H. Hyun, *J. Org. Chem.* **49**, 3043(1984).
- W.H. Pirkle, M.H. Hyun, and B. Bank, *J. Chromatogr.* **316**, 585 (1984).
- W.H. Pirkle, and M.H. Hyun, *J. Chromatogr.* **322**, 287 (1985).
- W.H. Pirkle, and M.H. Hyun, *J. Chromatogr.* **322**, 295 (1985).
- A. Gringanz, "Drugs, How they Act and Why," The C.V. Mosby Company, St. Louis (1978).
- I.W. Wainer, and T.D. Doyle, *LC Magazine* **2**, 88 (1984).
- A.M. Barret, and V.A. Cullulm, *Br. J. Pharmac.* **34**, 43 (1968).
- J.A. Thompson, J.L. Holtzman, M. Tsuru, and C.L. Lerman, *J. Chromatogr.* **238**, 470 (1982).
- W. Linder, and G. Uray, Abstract for 8th International Symposium on Column Chromatography, 2P-G2, New York, May (1984).
- I.W., Wainer, T.D. Doyle, K.H. Donn, and J.R. Powell, *J. Chromatogr. Biomed. Appl.* **306**, 405 (1984).
- I.W. Wainer, T.D., Doyle, Z. Hamidzadeh, and M. Aldridge, *J. Chromatogr.* **261**, 123 (1983).
- J. Hermansson, *J. Chromatogr.* **269**, 71 (1983).
- L.R. Snyder and J.J. Kirkland, "Introduction to Modern Chromatography", 2nd ed.; John Wiley and Sons, Inc., New York (1979).